Results 71 to 80 of about 7,464 (211)
Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer
Molecular Oncology, EarlyView.COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...Rodrigo Dienstmann, Eduardo García‐Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd, Ian Miller, Janick Selves, Nadja Meindl‐Beinker, Fiorella Ruiz‐Pace, Elena Élez, Raquel Comas‐Navarro, Frank Lincoln, Dirk Fey, Gift Nyamundanda, Aoife Nolan, Joern Lewin, Raquel Perez‐Lopez, Jonathan Briody, Kathleen Bennett, Walter Kolch, David Matallanas, Alexander Kel, Enrique Arenas, Joaquín Arribas, Bart Ghesquière, Josep Tabernero, Julie Meilleroux, Deborah McNamara, Ray McDermott, Marvin Lim, Mary O'Reilly, Brian Bird, Lisa Stack, Lucia Moloney, Patrick Morris, Keith Egan, Maciej Milewski, Lars Scheuer, Joachim Behringer, Georg Bolz, Ramon Salazar, Cristina Santos, Andrea Ruiz, Orla Casey, Verena Murphy, Matthias Ebert, Livio Trusolino, Diether Lambrechts, Anguraj Sadanandam, Catherine Sautès‐Fridman, Jochen Prehn, Paolo Nuciforo, Jacques Fieschi, Florence Monville, Darran O'Connor, Wolf Fridman, Annette Byrne +61 morewiley +1 more sourceKeratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer
Molecular Oncology, EarlyView.Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer +13 morewiley +1 more sourceSomatic mutational landscape in von Hippel–Lindau familial hemangioblastoma
Molecular Oncology, EarlyView.The causes of central nervous system (CNS) hemangioblastoma in Von Hippel–Lindau (vHL) disease are unclear. We used Whole Exome Sequencing (WES) on familial hemangioblastoma to investigate events that underlie tumor development. Our findings suggest that VHL loss creates a permissive environment for tumor formation, while additional alterations ...Maja Dembic, Anne Nørremølle, Lilian Bomme Ousager, Lars van Brakel Andersen, Marie Louise Mølgaard Binderup, Mads Thomassen +5 morewiley +1 more sourceDifferential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease
Molecular Oncology, EarlyView.In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales +11 morewiley +1 more sourceCCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3
Molecular Oncology, EarlyView.PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets +12 morewiley +1 more sourceCD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer
Molecular Oncology, EarlyView.Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu +8 morewiley +1 more sourceKDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan +16 morewiley +1 more sourceHeterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil
Molecular Oncology, EarlyView.EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig +10 morewiley +1 more sourceA facility to Search for Hidden Particles (SHiP) at the CERN SPS [PDF]
, 2015 A new general purpose fixed target facility is proposed at the CERN SPS
accelerator which is aimed at exploring the domain of hidden particles and make
measurements with tau neutrinos. Hidden particles are predicted by a large
number of models beyond the Alaoui, M. A. El, Anelli, M., Aoki, S., Arduini, G., Back, J. J., Bagulya, A., Baldini, W., Baranov, A., Barker, G. J., Barsuk, S., Battistin, M., Bauche, J., Bay, A., Bayliss, V., Bellagamba, L., Bencivenni, G., Bertani, M., Bezshyyko, O., Bick, D., Bingefors, N., Blondel, A., Bogomilov, M., Bonacorsi, D., Bondarenko, D., Bonivento, W., Borburgh, J., Boyarsky, A., Bradshaw, T., Brenner, R., Breton, D., Brook, N., Bruschi, M., Buonaura, A., Buontempo, S., Cadeddu, S., Calcaterra, A., Calviani, M., Campanelli, M., Capoccia, C., Cecchetti, A., Chatterjee, A., Chauveau, J., Chepurnov, A., Chernyavskiy, M., Ciambrone, P., Cicalo, C., Conti, G., Cornelis, K., Courthold, M., D'Ambrosio, N., Dallavalle, M. G., De Lellis, G., De Serio, M., Dedenko, L., Di Crescenzo, A., Di Marco, N., Dib, C., Dietrich, J., Dijkstra, H., Domenici, D., Donskov, S., Druzhkin, D., Ebert, J., Egede, U., Egorov, A., Egorychev, V., Enik, T., Etenko, A., Fabbri, F., Fabbri, L., Fedorova, G., Felici, G., Ferro-Luzzi, M., Fini, R. A., Franke, M., Fraser, M., Galati, G., Giacobbe, B., Goddard, B., Golinka-Bezshyyko, L., Golubkov, D., Golutvin, A., Gorbunov, D., Graverini, E., Grenard, J-L, Guler, A. M., Hagner, C., Hakobyan, H., Helo, J. C., Horvath, D., Iacovacci, M., Iaselli, G., Jacobsson, R., Kadenko, I., Kamiscioglu, C., Kamiscioglu, M., Khaustov, G., Khotjansev, A., Kilminster, B., Kim, V., Kitagawa, N., Kodama, K., Kolesnikov, A., Kolev, D., Komatsu, M., Konovalova, N., Koretskiy, S., Korolko, I., Korzenev, A., Kovalenko, S., Kudenko, Y., Kuznetsova, E., Lacker, H., Lai, A., Lanfranchi, G., Lauria, A., Lebbolo, H., Levy, J. -M., Lista, L., Loverre, P., Lukiashin, A., Lyubovitskij, V. E., Malinin, A., Manfredi, M., Marrone, A., Matev, R., Mermod, P., Messomo, E. N., Mikado, S., Mikhaylov, Yu., Miller, J., Milstead, D., Mineev, O., Mingazheva, R., Mitselmakher, G., Miyanishi, M., Monacelli, P., Montanari, A., Montesi, M. C., Morello, G., Morishima, K., Movtchan, S., Murzin, V., Naganawa, N., Naka, T., Nakamura, M., Nakano, T., Nurakhov, N., Obinyakov, B., Ocalan, K., Ogawa, S., Oreshkin, V., Orlov, A., Osborne, J., Pacholek, P., Panman, J., Paoloni, A., Paparella, L., Pastore, A., Patel, M., Perillo-Marcone, A., Petridis, K., Petrushin, M., Poli-Lener, M., Polukhina, N., Polyakov, V., Prokudin, M., Puddu, G., Pupilli, F., Rademakers, F., Rakai, A., Rawlings, T., Redi, F., Ricciardi, S., Rinaldesi, R., Roganova, T., Rogozhnikov, A., Rokujo, H., Romaniouk, A., Rosa, G., Rostovtseva, I., Rovelli, T., Ruchayskiy, O., Ruf, T., Saitta, G., Samoylenko, V., Samsonov, V., Saputi, A., Sato, O., Schmidt-Parzefall, W., Serra, N., Sgobba, S., Shaposhnikov, M., Shatalov, P., Shaykhiev, A., Shchutska, L., Shevchenko, V., Shibuya, H., SHiP Collaboration, Shitov, Y., Silverstein, S., Simone, S., Skorokhvatov, M., Smirnov, S., Solodko, E., Sosnovtsev, V., Spighi, R., Spinetti, M., Starkov, N., Storaci, B., Strabel, C., Strolin, P., Takahashi, S., Teterin, P., Tioukov, V., Tommasini, D., Treille, D., Tsenov, R., Tshchedrina, T., Ull, A. Sanz, Ustyuzhanin, A., van Herwijnen, E., Vankova-Kirilova, G., Vannucci, F., Venturi, V., Villa, M., Vincke, Heinz, Vincke, Helmut, Vladymyrov, M., Xella, S., Yalvac, M., Yershov, N., Yilmaz, D., Yilmazer, A. U., Zaitsev, Y., Zoccoli, A. +235 morecore +1 more sourceAdaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis
Molecular Oncology, EarlyView.CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová +10 morewiley +1 more source
